EpitoMAP, Animal Allergy Clinical Laboratories (AACL) & Kogyo Entered into a Collaboration and License Agreement to develop CRE-DR-B
- As per the agreement, Kogyo has the right to conduct preclinical & clinical development, manufacturing & commercialization of CRE-DR-B for allergic diseases such as canine Atopic Dermatitis in Japan
- The details regarding the upfront payment, milestones & royalties remain undisclosed. These funds will be utilized by EpitoMAP & AACL for the development of CRE-DR-B overseas, humanized CRE-DR, & therapeutic vaccines against COVID-19, FIP caused by pathogenic coronavirus in cats & FIPV
- CRE-DR-B is a chimeric antibody derived from mouse x dog IgG-B mAB called CRE-DR, which targets human and canine IgEs. CRE-DR eliminates and inactivates IgE-producing B cells, the fundamental cause of allergies
Ref: PR Newswire | Image: EpitoMAP
Related News:- ASLAN Pharmaceuticals Entered into a License Agreement with Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at firstname.lastname@example.org.